Page Title
This is a Paragraph. Click on "Edit Text" or double click on the text box to start editing the content and make sure to add any relevant details or information that you want to share with your visitors.
PyroCells
Personalized Cancer Vaccine Platform
​Current Limitations in Cancer Immunotherapy
​
Tumor Heterogeneity: Tumors often consist of multiple subpopulations of cancer cells, each with different antigen profiles. Focusing on a single target fails to address the full spectrum of tumor diversity, allowing untargeted subpopulations to survive and drive disease recurrence.
Antigen Loss and Immune Escape: Under therapeutic pressure, cancer cells can downregulate or lose the targeted antigen, effectively evading immune recognition. As these resistant clones dominate, the therapy becomes increasingly ineffective over time.
Minor Antigen-Expressing Populations: In many cancers, the cells that strongly express a given antigen represent only a small fraction of the tumor mass. Antigen-specific therapies effectively eliminate that subset, but the majority of tumor cells—expressing minimal or no target antigen—often remain and progress.
Limited Immune Engagement: By design, antigen-specific strategies direct the immune response at a narrow set of targets. This restricted scope can leave considerable tumor subpopulations untouched, limiting overall therapeutic success.
Overall, relying on a single or limited set of tumor-associated antigens constrains the breadth and depth of immune engagement, ultimately hindering long-term efficacy in heterogeneous and rapidly evolving cancers.
PyroCells - Delta and Alpha
​
Antigen-Agnostic Approach
Uses the whole tumor as the immunogen, triggering a broad and durable immune response against diverse tumor antigens to generate a robust, multi-antigen immune response. Unlike antigen-specific therapies (e.g., mAbs, mRNA, peptide vaccines), PyroCells is designed to overcome tumor heterogeneity and reduce immune escape mechanisms.​​​​​
Highly Immunogenic Composition
Each PyroCells vaccine is genetically and chemically modified to enhance antigen presentation and immune activation, ensuring a strong, multi-antigen immune response for better cancer control. PyroCells is engineered with proprietary immunostimulatory components, enhancing T cell priming and activation.​​​​​
Superior Engineering Efficiency
PyroCells achieves a 98% engineering efficiency, compared to industry-standard 35% efficiency in cell-based immunotherapies. This results in more potent immune activation and better consistency in clinical applications.​​​​​
Correct Clinical Context
Designed for early disease intervention, adjuvant therapy, and use with checkpoint inhibitors (CPI) to maximize immune response. Point-of-care manufacturing within 24 hours, making PyroCells scalable and accessible globally.​​
Rapid Manufacturing
Our automated production system enables the creation of patient-specific vaccines within 24 hours—right at the surgical site—facilitating swift intervention without compromising vaccine quality.​​
Validated Preclinical Success
In preclinical models, PyroCells achieved 100% tumor protection, highlighting its potential to deliver robust, durable immunity against a wide range of tumors.
PyroCells vaccines are created using the patient's own tumor and are designed to activate an immune response against heterogeneous cancer antigens, not a single or select few.
